Document is current
Any future updates will be listed below
-
Authors
Fujimura, Takaaki
Furugaki, Koh https://orcid.org/0009-0008-9626-2027
Mizuta, Hayato https://orcid.org/0009-0006-3553-9091
Muraoka, Satoshi
Nishio, Makoto
Adachi, Jun https://orcid.org/0000-0003-1220-3246
Uchibori, Ken https://orcid.org/0000-0003-1491-923X
Miyauchi, Eisaku https://orcid.org/0000-0002-6837-6392
Hayashi, Hidetoshi
Katayama, Ryohei https://orcid.org/0000-0001-7394-895X
Yoshiura, Shigeki https://orcid.org/0000-0002-2401-148X
- License Information
-
More Information
Article History
Received: 7 September 2023
Accepted: 7 November 2024
First Online: 17 November 2024
Competing interests
: T.F., S.Y., K.F. and H.M. are employees of Chugai Pharmaceutical Co., Ltd., and declare no conflict of interest. S.M. and J.A. declare no conflict of interest. M.N. received honoraria for lectures from Ono Pharmaceutical, Takeda Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, Pfizer, Chugai Pharmaceutical, Eli Lilly, Nippon Kayaku, Taiho Pharmaceutical, AstraZeneca, AbbVie, Boehringer-Ingelheim, MSD, Novartis, Merck, Janssen. E.M. received grants from Chugai Pharmaceutical, Eli Lily Japan, and honoraria from Ono Pharmaceutical, Eisai, Otsuka pharmaceutical, Thermo Fisher Scientific, Bristol Myers Squibb, Daiichi Sankyo, Pfizer, Takeda Pharmaceutical, Chugai Pharmaceutical, Amgen, Thermo Fisher Scientific, Eli Lilly Japan, Nippon Kayaku, Taiho Pharmaceutical, Sysmex, Boehringer-Ingelheim Japan, MSD, Novartis, Kyowa Kirin, Merck, and participated on Advisory Board of Chugai Pharmaceutical, Boehringer-Ingelheim Japan, Eli Lilly Japan, Merck, Daiichi Sankyo, Ono Pharmaceutical. K.U. received honoraria for lectures from Ono Pharmaceutical, Takeda Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, Thermo Fisher Scientific, Chugai Pharmaceutical, Eli Lilly, AstraZeneca, Novartis, Merck. H.H. received support from Guardant Health Japan, and grants from IQVIA Services JAPAN, SYNEOS HEALTH CLINICAL, EPS, Nippon Kayaku, Takeda Pharmaceutical, MSD, Amgen, Taiho Pharmaceutical, Bristol Myers Squibb, Janssen Pharmaceutical, CMIC, Pfizer R&D Japan, Labcorp Development Japan, Kobayashi Pharmaceutical, Pfizer Japan, Eisai, EP-CRSU, Shionogi & Co., Ltd., Otsuka pharmaceutical, GlaxoSmithKline, Sanofi, Chugai Pharmaceutical, Boehringer-Ingelheim Japan, SRL Medisearch, PRA Health Sciences, Astellas Pharma, Ascent Development Services, Bayer Yakuhin, and honoraria from Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Pfizer Japan, Boehringer-Ingelheim Japan, Merck Biopharma, 3H Clinical Trial, Novartis Pharma, Bristol Myers Squibb, Amgen, Sysmex, Takeda Pharmaceutical. Dr. Ryohei Katayama is an Associate Editor for npj Precision Oncology, and received research grants from Chugai Pharmaceutical and TOPPAN Inc.
